This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. ME, IBIO, GLYC, AEON, OBSV, ORGS, AEZS, CPHI, NRBO, and MTNBShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include 23andMe (ME), iBio (IBIO), GlycoMimetics (GLYC), AEON Biopharma (AEON), ObsEva (OBSV), Orgenesis (ORGS), Aeterna Zentaris (AEZS), China Pharma (CPHI), NeuroBo Pharmaceuticals (NRBO), and Matinas Biopharma (MTNB). These companies are all part of the "medical" sector. Novus Therapeutics vs. Its Competitors 23andMe iBio GlycoMimetics AEON Biopharma ObsEva Orgenesis Aeterna Zentaris China Pharma NeuroBo Pharmaceuticals Matinas Biopharma Novus Therapeutics (NASDAQ:NVUS) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Do insiders and institutionals have more ownership in NVUS or ME? 36.1% of 23andMe shares are owned by institutional investors. 2.2% of Novus Therapeutics shares are owned by insiders. Comparatively, 26.3% of 23andMe shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is NVUS or ME more profitable? Novus Therapeutics has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Novus Therapeutics' return on equity of -133.49% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets Novus TherapeuticsN/A -133.49% -30.52% 23andMe -183.39%-170.07%-62.13% Which has stronger earnings & valuation, NVUS or ME? Novus Therapeutics has higher earnings, but lower revenue than 23andMe. Novus Therapeutics is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovus TherapeuticsN/AN/A-$16.01M-$21.58-0.1423andMe$208.78M0.06-$666.70M-$15.45-0.03 Which has more risk & volatility, NVUS or ME? Novus Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Does the media prefer NVUS or ME? In the previous week, 23andMe had 12 more articles in the media than Novus Therapeutics. MarketBeat recorded 12 mentions for 23andMe and 0 mentions for Novus Therapeutics. 23andMe's average media sentiment score of 0.47 beat Novus Therapeutics' score of 0.00 indicating that 23andMe is being referred to more favorably in the news media. Company Overall Sentiment Novus Therapeutics Neutral 23andMe Neutral Do analysts rate NVUS or ME? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.0023andMe 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Summary23andMe beats Novus Therapeutics on 8 of the 13 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.39M$783.00M$5.49B$9.01BDividend YieldN/A4.84%5.39%4.10%P/E Ratio-0.141.2926.7120.06Price / SalesN/A219.27419.59119.24Price / CashN/A23.4436.1356.90Price / Book0.236.008.065.59Net Income-$16.01M-$27.64M$3.16B$248.50M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$3.06+9.7%N/A+15.8%$4.39MN/A-0.147High Trading VolumeME23andMeN/A$0.50-35.3%N/A-93.6%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIBIOiBio1.6463 of 5 stars$0.75-1.7%$4.30+473.4%-62.1%$12.39M$375K0.00100GLYCGlycoMimetics2.0406 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450Positive NewsHigh Trading VolumeAEONAEON Biopharma3.5169 of 5 stars$0.80+4.9%$360.00+45,058.1%-98.8%$9.01MN/A4.435Positive NewsOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150ORGSOrgenesis1.8303 of 5 stars$1.53+3.7%N/AN/A$7.34M$662K0.00150Gap UpAEZSAeterna ZentarisN/A$3.40+1.8%N/A-22.2%$6.10M$2.37M-0.2320Gap DownCPHIChina Pharma0.3241 of 5 stars$1.81+1.1%N/A-93.2%$5.90M$4.30M0.00250News CoverageNRBONeuroBo PharmaceuticalsN/A$0.64+2.1%N/A-86.1%$5.54MN/A0.0010News CoverageGap UpMTNBMatinas Biopharma0.1367 of 5 stars$0.90+1.5%N/AN/A$4.59MN/A-0.1930Positive NewsGap Down Related Companies and Tools Related Companies ME Alternatives IBIO Alternatives GLYC Alternatives AEON Alternatives OBSV Alternatives ORGS Alternatives AEZS Alternatives CPHI Alternatives NRBO Alternatives MTNB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
